Search results
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Motley Fool via Yahoo Finance· 12 hours agoThat's because CRISPR Therapeutics recently launched its very first product, Casgevy, for blood...
Gene therapy and employee benefits: from science fiction to medical reality
BenefitsPRO· 6 days agoAs of late May 2024, 14 gene therapies are FDA-approved for a range of conditions including sickle...
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June...
Benzinga· 4 hours agoMid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX,...
Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
Reuters· 6 days ago, opens new tab said on Monday its experimental treatment for an inherited blood disorder met the main goal in a late-stage study. The drug candidate, mitapivat, significantly reduced the need ...
Why Is Agios Pharmaceuticals Stock Trading Higher On Monday? - Agios Pharmaceuticals (NASDAQ:AGIO)
Benzinga· 6 days agoShares Agios Pharmaceuticals Inc.’s AGIO climbed after it was revealed a Phase 3 ENERGIZE-T study of...
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Motley Fool via Yahoo Finance· 5 days agoCasgevy treats or functionally cures a pair of inherited blood diseases, sickle cell disease (SCD)...
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) the Leading Gene Therapy Stock to Buy Now?
Insider Monkey via Yahoo Finance· 6 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 6 days ago– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key Secondary Endpoints Evaluating Additional Measures
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 2 days agoVertex and partner Crispr Therapeutics gained Food and Drug Administration approval for a...
Cathie Wood Invests In 2 Biotechnology Stocks – Are They Worth Buying?
Benzinga via Yahoo Finance· 2 days agoWith her ARK Innovation ETF (ARKK: NYSE Arca), Cathie Wood makes large wagers on biotech businesses...